NCT07063875View on ClinicalTrials.gov

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Uveal MelanomaMetastatic Uveal MelanomaMetastatic Uveal Melanoma in the Liver
Interventions
DRUG

Aldesleukin

IL-2 in combination with Tebentafusp

Trial Locations (2)

2010

RECRUITING

Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney

3004

NOT_YET_RECRUITING

Alfred Hospital, Melbourne

All Listed Sponsors
lead

St Vincent's Hospital, Sydney

OTHER